CR20200602A - Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje - Google Patents
Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltajeInfo
- Publication number
- CR20200602A CR20200602A CR20200602A CR20200602A CR20200602A CR 20200602 A CR20200602 A CR 20200602A CR 20200602 A CR20200602 A CR 20200602A CR 20200602 A CR20200602 A CR 20200602A CR 20200602 A CR20200602 A CR 20200602A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- voltage
- potassium channel
- gated potassium
- bioavailability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>En determinadas modalidades, la presente descripción se dirige a métodos y usos para tratar trastornos convulsivos en un ser humano, en los que los métodos y usos comprenden la administración oral de una cantidad terapéuticamente efectiva del modulador alostérico del canal de potasio dependiente de voltaje, <em>N</em>- [4- (6-fluoro-3,4-dihidro-5 1<em>H</em>-isoquinolin-2-il) -2,6-dimetilfenil] -3,3-dimetilbutanamida (Compuesto A), al ser humano que lo necesite, por ejemplo, en condiciones de alimentación. La presente descripción se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| PCT/US2019/031872 WO2019217924A1 (en) | 2018-05-11 | 2019-05-10 | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200602A true CR20200602A (es) | 2021-03-02 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200602A CR20200602A (es) | 2018-05-11 | 2019-05-10 | Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US11135214B2 (es) |
| EP (2) | EP4279133A3 (es) |
| JP (2) | JP7570924B2 (es) |
| KR (1) | KR20210020892A (es) |
| CN (1) | CN112384216A (es) |
| AU (2) | AU2019265002C1 (es) |
| BR (1) | BR112020022713A2 (es) |
| CA (1) | CA3099292A1 (es) |
| CL (1) | CL2020002932A1 (es) |
| CO (1) | CO2020015476A2 (es) |
| CR (1) | CR20200602A (es) |
| DK (1) | DK3790548T3 (es) |
| EA (1) | EA202092720A1 (es) |
| ES (1) | ES2964409T3 (es) |
| FI (1) | FI3790548T3 (es) |
| GE (1) | GEP20237527B (es) |
| HR (1) | HRP20231447T1 (es) |
| HU (1) | HUE064326T2 (es) |
| LT (1) | LT3790548T (es) |
| MA (1) | MA52569B1 (es) |
| MD (1) | MD3790548T2 (es) |
| MX (2) | MX2020012008A (es) |
| PE (1) | PE20211211A1 (es) |
| PH (1) | PH12020551898A1 (es) |
| PL (1) | PL3790548T3 (es) |
| PT (1) | PT3790548T (es) |
| RS (1) | RS64922B1 (es) |
| SG (1) | SG11202011102TA (es) |
| SI (1) | SI3790548T1 (es) |
| SM (1) | SMT202300399T1 (es) |
| UA (1) | UA127229C2 (es) |
| WO (1) | WO2019217924A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099292A1 (en) | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| AU2020380961A1 (en) | 2019-11-08 | 2022-05-26 | Xenon Pharmaceuticals Inc. | Methods of treating depressive disorders |
| PE20221169A1 (es) * | 2019-12-06 | 2022-07-25 | Xenon Pharmaceuticals Inc | Uso de un abridor de canal de potasio kv7 para tratar el dolor |
| AU2022220675A1 (en) | 2021-02-09 | 2023-09-21 | Xenon Pharmaceuticals Inc. | Voltage-gated potassium channel opener for use in treating anhedonia |
| TW202245743A (zh) * | 2021-02-09 | 2022-12-01 | 加拿大商再諾製藥公司 | 治療癲癇症之聯合療法 |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
| KR102694996B1 (ko) * | 2021-10-27 | 2024-08-13 | 상하이 지멍 바이오파마 아이엔씨 | 칼륨 채널 조절제로 사용되는 화합물 및 이의 제조 및 응용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| JP2009535370A (ja) | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| JP5419691B2 (ja) * | 2006-08-23 | 2014-02-19 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体 |
| US20100323016A1 (en) | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| EA201290659A1 (ru) | 2010-01-20 | 2013-05-30 | Глэксо Груп Лимитед | Новая композиция ретигабина |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| CA3099292A1 (en) | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
-
2019
- 2019-05-10 CA CA3099292A patent/CA3099292A1/en active Pending
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/en active Pending
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-10 AU AU2019265002A patent/AU2019265002C1/en active Active
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 JP JP2020562201A patent/JP7570924B2/ja active Active
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/en active Active
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 SM SM20230399T patent/SMT202300399T1/it unknown
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko unknown
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/en active Application Filing
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-10 MX MX2023013247A patent/MX2023013247A/es unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en active Pending
-
2024
- 2024-04-26 US US18/648,049 patent/US20240316032A1/en active Pending
- 2024-05-30 US US18/679,045 patent/US20240316033A1/en active Pending
- 2024-09-17 AU AU2024219794A patent/AU2024219794A1/en active Pending
- 2024-10-09 JP JP2024177074A patent/JP2025011203A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013247A (es) | Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje. | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| MX2021014960A (es) | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. | |
| WO2019199861A3 (en) | Hemp extract for treatment of pain in animals | |
| TW200728289A (en) | Non-basic melanin concentrating hormone receptor-1 antagonists | |
| MX2022006877A (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor. | |
| MX2021014158A (es) | Uso de cannabidiol en el tratamiento de espasmos epilepticos. | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| MX2022005490A (es) | Metodos para el tratamiento de trastornos depresivos. | |
| AU2020255100A8 (en) | N-heteroaromatic amide derivatives for treatment of cancer | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| MX2024004994A (es) | Métodos para tratar el cáncer de ovário con extracto de cáñamo. | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2024011403A (es) | Tratamiento con mirdametinib. | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| EP4233850A3 (en) | Capsule formulations | |
| PH12021551839A1 (en) | Crystal of diarylthiohydantoin compound | |
| CO2023011948A2 (es) | Terapia conjunta para el tratamiento de trastornos convulsivos | |
| GEP20247629B (en) | Alcohol derivatives as kv7 potassium channel openers | |
| MX2019015849A (es) | Nuevos compuestos de espirolactona. | |
| MX2022001285A (es) | Composicion y metodos para el tratamiento de trastornos anales y rectales. | |
| RU2018111990A (ru) | Лекарственные экстракты растений амброзии | |
| MX2022007768A (es) | Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas. |